The second major Medicare agreement significantly expands TONMYA's addressable patient population. With 150 sales reps now in the field, the next catalyst is prescription volume data from the expanded coverage base. Monitor next quarterly earnings for TONMYA revenue trajectory and any additional payer wins.
Price Chart
Executive Summary
Tonix Pharmaceuticals announced a second major managed Medicare payer agreement for TONMYA, effective immediately, adding approximately 21 million Medicare lives. Total commercial and government payer coverage for TONMYA now reaches approximately 166 million covered lives (53% of total U.S. lives). The sales force has been expanded to 150 representatives, up from 100 previously.
Key Facts
- Second major managed Medicare agreement for TONMYA, effective immediately
- Adds approximately 21 million Medicare lives (38% of ~55 million U.S. Medicare lives)
- Total Medicare coverage now 32 million lives (58% of U.S. Medicare lives)
- Total commercial and government payer coverage reaches ~166 million covered lives (53% of ~314 million total U.S. lives)
- Sales force expanded to 150 representatives (50 new reps activated)
- TONMYA is the first new fibromyalgia treatment approved in over 15 years (FDA approved Aug 15, 2025)
Financial Impact
No financial figures provided; coverage expansion supports revenue ramp for TONMYA launch
Risk Factors
- No revenue or prescription figures disclosed — launch trajectory remains unquantified
- Competition from existing fibromyalgia treatments and potential generic cyclobenzaprine
- Company's need for additional financing as noted in risk factors
Investment Themes
Documents Analyzed
This report is based on 5 SEC documents filed with EDGAR.
| Document | Accession Number |
|---|---|
| 8-K Filing (Primary) | 0001493152-26-043644 |
| Document: form8-k.htm | 0001493152-26-043644 |
| Document: 0001493152-26-043644-index-headers.html | 0001493152-26-043644 |
| Document: 0001493152-26-043644-index.html | 0001493152-26-043644 |
| Document: 0001493152-26-043644.txt | 0001493152-26-043644 |
Filters
| Type | Now | ||||
|---|---|---|---|---|---|
Oct 19, 2026 7d ago | Press Release | $5.73 | awaiting T+20 | — | $5.30 (−7.50%) |
Oct 15, 2026 11d ago | 8-K | $6.42 | awaiting T+20 | — | $5.30 (−17.45%) |
Oct 2, 2026 23d ago | 8-K | $8.07 | awaiting T+20 | — | $5.30 (+34.32%) |
Sep 22, 2026 4w ago | 8-K | $10.59 $5.78 | ▼ −45.42% | ▼ −44.86% | $5.30 (−49.95%) |
Sep 8, 2026 6w ago | 8-K | $13.16 $7.70 | ▼ −41.49% | ▼ −43.46% | $5.30 (−59.73%) |
Aug 10, 2026 11w ago | 8-K | $12.59 $13.16 | ▲ +4.53% | ▲ +5.44% | $5.30 (−57.90%) |
Aug 10, 2026 11w ago | Press Release | $12.59 $13.16 | ▲ +4.53% | ▲ +5.44% | $5.30 (−57.90%) |
Aug 3, 2026 12w ago | 8-K | $10.67 $14.10 | ▲ +32.15% | ▲ +30.91% | $5.30 (−50.33%) |
Jul 27, 2026 13w ago | Press Release | $10.37 $12.45 | ▲ +20.06% | ▲ +16.76% | $5.30 (−48.89%) |
Jul 13, 2026 15w ago | 8-K | $11.71 $12.59 | ▲ +7.56% | ▲ +4.38% | $5.30 (−54.72%) |
US Market Status
Subscribe to SecBot
Get Real-Time SEC Filing Intelligence
Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.
Create a free account Live analysis, Telegram alerts, watchlists and the MCP server for subscribers